What is the market's earnings forecast for Humana next quarter?

What factors drove the changes in Humana's revenue and profit?

What is Humana's latest dividend and current dividend yield?

What is the revenue and EPS growth rate for Humana year over year?

What does Humana do and what are its main business segments?

What guidance did Humana's management provide for the next earnings period?

What were the key takeaways from Humana’s earnings call?

Did Humana beat or miss consensus estimates last quarter?

- **MA Growth Strategy**: Prioritizes retention over new sales, with channel mix focused on high-value segments. Stars recovery progress visible in '28, though '27 results disappointing.
- **Financial Discipline**: $17 EPS target reaffirmed despite $150M investments. Capital allocation balanced between M&A and debt management.
- **Key Metrics**: Reduced plan-to-plan sales (down YoY), 600K+ gaps closed in '28, and DCP timing-driven changes highlight operational focus.
- **Long-Term Vision**: Shift to LTV/Stars-driven margin, with 2026 MA margin doubling 2025 levels if Stars thresholds align.

**【CEO Summary Section】**
- **Medicare Advantage (MA) Growth Strategy**: Emphasized focus on retention over new sales, with new sales at the high end of expectations. Retention rates are a key metric, with reduced plan-to-plan sales (down year-over-year), indicating better member stability. However, specific growth targets are withheld due to operational capacity concerns.
- **Channel Mix Optimization**: Greater volume in high-performing partner and digital channels, which correlate with higher lifetime value. Avoiding outsized sales in low-margin plans to maintain operational efficiency.
- **Stars Program Recovery**: Bonus Year '27 results were disappointing but consistent with expectations. Bonus Year '28 shows early operational progress, with 600,000 more gaps closed year-over-year, though final results depend on thresholds.
- **Long-Term Value (LTV) Framework**: Shift to lifetime value and NPV as primary metrics, balancing short-term margin with long-term sustainability. Avoiding the cycle of low-margin, high-growth products.

**【CFO Financial Commentary】**
- **Third-Quarter Performance**: Solid execution with medical cost trends in line with expectations. Reaffirmed full-year adjusted EPS outlook of $17, despite incremental investments ($150 million) in Stars and network management.
- **Capital Allocation**: Proceeding with non-core asset sales (e.g., Enclara Pharmacia) and M&A (e.g., Villages Health). Debt-to-cap ratio at 40.3%, targeting ~40% long-term. Share buybacks offset dilution from stock-based compensation.
- **Balance Sheet Management**: DCP metric reflects timing variations, not reserve levels. IBNR consistency supports claims reserve strength, despite individual MA membership decline.

**【Q&A Highlights】**
- **Membership Growth Dynamics**: New sales at the high end of expectations, but operational capacity limits transparency on exact numbers. Focus on channel mix (e.g., digital, high-performing partners) to mitigate risk.
- **Stars Mitigation Efforts**: Proactive measures with providers, including contract changes and Stars mitigation programs. Progress in 2026 will depend on provider partnerships and Stars thresholds.
- **2026 Outlook**: MA margin expected to double 2025 levels, driven by product design and channel mix. However, final results hinge on Stars performance and operational execution.
- **Market Trends**: CMS forecasts suggest mid-single-digit MA growth, consistent with historical patterns. Humana remains below or at parity with competitors in key geographies, limiting fee-for-service attrition risk.

Humana Inc. (HUM) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

HUM

HUM fundamentals

You can ask Aime